诺华 承 诺 与残障人士共事并 为 他 们 提供合理的便利 设 施。如果您由于健康状况或残障 在招聘 过 程的任何 环 节 需要合理便利 设 施 或者 为 了履行 职 位的基本 职 能 请发 送 电 子 邮 件至 [email protected] 告知您的需求和 联 系方式，并在 邮 件中附上您的 ...

V Novartisu spodbujamo inovativnost in razvoj ter delujemo na številnih področjih. Tudi vi lahko postanete del tega, del naše zgodbe. Pridružite se naši ustvarjalni skupnosti strokovnjakov in našli ...

Sr. Spec. DDIT IES Cloud Engineering Regular, Full time Universal Hierarchy Node India +Alternative Locations Hyderabad (Office) Giu 05, 2025 Assoc. Dir. DDIT IES Cloud Engineering Regular, Full time ...

The mental health and wellbeing of our people is vitally important. It is a natural extension of our company’s purpose to ...

Report side effects What is a side effect? A side effect is any unwanted medical occurrence in a patient who has been given a pharmaceutical product that may or may not have been caused by treatment ...

Meet the Novartis Board of Directors, responsible for the direction, strategy, and administration of this global pharmaceutical and biotech company.

Health disparities in Canada go beyond individual health issues - they underscore deeper societal injustices that undermine our social fabric. These inequities highlight the existence of systemic ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

April 26, 2023 Today Novartis has published updated 2022 quarterly and full year segment financials reflecting transfers of Sandoz biotechnology manufacturing services to other companies’ activities ...

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the ...

Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 46 of the Interim Financial Report. Unless otherwise noted, ...

Remibrutinib, a highly selective oral BTK inhibitor, was well-tolerated and demonstrated a favorable safety profile, including balanced liver function tests in active and placebo arms across both ...